PS

Phani Srikanth Peesapati

Active Director Managing Director DIN 11592053
DIN 11592053 First appointment Mar 2026 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Phani Srikanth Peesapati

Data last updated:

Phani Srikanth Peesapati is a Managing Director at Manophani Medxdeals Pharmaceuticals Private Limited (since 2026). The company operates in Healthcare.

DIN 11592053
Primary Designation Managing Director
Industry Healthcare
First Appointment 09 Mar 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Managing Director09 Mar 20262026Active

Directorship timeline

Open interactive timeline →
Manophani Medxdeals Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Phani Srikanth Peesapati

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Phani Srikanth Peesapati

Phani Srikanth Peesapati currently holds 1 directorship: Manophani Medxdeals Pharmaceuticals Private Limited (Managing Director, since 09 Mar 2026).

Phani Srikanth Peesapati was first appointed on 09 Mar 2026 as Managing Director at Manophani Medxdeals Pharmaceuticals Private Limited.

The current boards of Phani Srikanth Peesapati's companies include Manoja Vemuri (Manophani Medxdeals Pharmaceuticals Private Limited), Pallavajhala Sathya Sai Venkata Laxmi (Manophani Medxdeals Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available